Catalent Inc (NASDAQ:CTLT)’s share price traded up 4% on Tuesday . The stock traded as high as $25.81 and last traded at $25.70, with a volume of 768,529 shares trading hands. The stock had previously closed at $24.70.

Several equities research analysts recently issued reports on the company. TheStreet raised Catalent from a “sell” rating to a “hold” rating in a research note on Wednesday, August 17th. Zacks Investment Research lowered Catalent from a “hold” rating to a “strong sell” rating in a research note on Monday, August 15th. Jefferies Group reissued a “hold” rating on shares of Catalent in a research note on Thursday, August 4th. Wells Fargo & Co. raised Catalent from a “market perform” rating to an “outperform” rating in a research note on Tuesday, June 21st. Finally, Bank of America Corp. raised Catalent from a “neutral” rating to a “buy” rating and set a $28.00 price objective for the company in a research note on Monday, June 20th. They noted that the move was a valuation call. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $26.50.

The stock’s 50 day moving average is $24.66 and its 200-day moving average is $25.46. The firm has a market capitalization of $3.12 billion and a P/E ratio of 15.56.

In other Catalent news, major shareholder Blackstone Management Associat sold 8,785,539 shares of the stock in a transaction on Thursday, June 9th. The stock was sold at an average price of $24.51, for a total value of $215,333,560.89. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Matthew M. Walsh sold 21,197 shares of the stock in a transaction on Friday, May 27th. The stock was sold at an average price of $28.85, for a total value of $611,533.45. Following the completion of the sale, the insider now owns 105,688 shares of the company’s stock, valued at approximately $3,049,098.80. The disclosure for this sale can be found here.

Catalent, Inc is a provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. The Company’s segments include Oral Technologies, Medication Delivery Solutions, and Development and Clinical Services. The Oral Technologies segment provides advanced oral delivery technologies, including formulation, development and manufacturing of oral dose forms for prescription and consumer health products across all phases of a molecule’s lifecycle.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.